Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing

Moum, 1997, Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990–93, Scand J Gastroenterol, 32, 1005, 10.3109/00365529709011217 Timmer, 1999, Incidence of ulcerative colitis 1980–1995. A prospective study in an urban population in Germany, Z Gastroenterol, 37, 1079 Travis, 2008, European evidence-based consensus on the management of ulcerative colitis: current management, J Crohns Colitis, 2, 24, 10.1016/j.crohns.2007.11.002 Bitton, 2001, Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis, Semin Gastrointest Dis, 12, 263 Satsangi, 2006, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, 55, 749, 10.1136/gut.2005.082909 Osterwald, 1990, Pharmaceutical development, Scand J Gastroenterol Suppl, 172, 43, 10.3109/00365529009091909 Brynskov, 1996, Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease, Scand J Gastroenterol, 216, 175, 10.3109/00365529609094572 Keller, 1998, Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen, Med Klin, 93, 294, 10.1007/BF03044864 Rochester, 2005, Ulcerative colitis therapy: importance of delivery mechanisms, Rev Gastroenterol Disord, 5, 215 Ewe, 1999, Inflammation does not decrease intra-luminal pH in chronic inflammatory bowel disease, Dig Dis Sci, 44, 1434, 10.1023/A:1026664105112 Raimundo, 1992, Gastrointestinal pH profiles in ulcerative colitis, Gastroenterology, 102, A681 Nugent, 2000, Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH dependent 5-ASA containing capsules (abstract T34), Gut, 47, A9 Christensen, 1990, Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man, Aliment Pharmacol Ther, 4, 523, 10.1111/j.1365-2036.1990.tb00499.x Dignass, 2009, Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis, Clin Gastroenterol Hepatol, 7, 762, 10.1016/j.cgh.2009.04.004 Bokemeyer, 2009, P169 — higher remission rates in patients with once-daily dosing compared to twice daily-dosing. An analysis of compliance in the once-daily vs. twice-daily PODIUM trial with mesalazine (Pentasa®) sachets, J Crohns Colitis, 3, S78, 10.1016/S1873-9946(09)60196-3 Regueiro, 2006, Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials, Inflamm Bowel Dis, 12, 979, 10.1097/01.mib.0000231495.92013.5e Prantera, 2009, Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol, Aliment Pharmacol Ther, 30, 908, 10.1111/j.1365-2036.2009.04117.x Marteau, 2005, Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study, Gut, 54, 960, 10.1136/gut.2004.060103 Marshall, 2000, Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis, Am J Gastroenterol, 95, 1628, 10.1111/j.1572-0241.2000.02180.x Nugent, 2001, Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut, 48, 571, 10.1136/gut.48.4.571 Lawrance, 2011, Topical agents for idiopathic distal colitis and proctitis, J Gastroenterol Hepatol, 26, 36, 10.1111/j.1440-1746.2010.06497.x Kruis, 2011, Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis, Aliment Pharmacol Ther, 33, 313, 10.1111/j.1365-2036.2010.04537.x Kamm, 2008, Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis, Gut, 57, 893, 10.1136/gut.2007.138248 Frøslie, 2007, Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort, Gastroenterology, 133, 412, 10.1053/j.gastro.2007.05.051 Ochsenkühn, 2011, Current misunderstandings in the management of ulcerative colitis, Gut, 60, 1294, 10.1136/gut.2010.218180 Kane, 2009, Controversies in mucosal healing in ulcerative colitis, Inflamm Bowel Dis, 15, 796, 10.1002/ibd.20875 Hanauer, 2005, Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial, Am J Gastroenterol, 100, 2478, 10.1111/j.1572-0241.2005.00248.x Hanauer, 2007, Delayed-release oral mesalamine 4.8g/day (800mg tablets) compared to 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial, Can J Gastroenterol, 21, 827, 10.1155/2007/862917 Hanauer, 2007, Once-daily, high-concentration MMX mesalamine in active ulcerative colitis, Gastroenterology, 132, 66, 10.1053/j.gastro.2006.10.011 Lichtenstein, 2007, Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis, Clin Gastroenterol Hepatol, 5, 95, 10.1016/j.cgh.2006.10.025 Pineton de Chambrun, 2010, Clinical implications of mucosal healing for the management of IBD, Nat Rev Gastroenterol Hepatol, 7, 15, 10.1038/nrgastro.2009.203 Lichtenstein, 2010, Importance of mucosal healing in ulcerative colitis, Inflamm Bowel Dis, 16, 338, 10.1002/ibd.20997 Froslie, 2007, Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort, Gastroenterology, 133, 412, 10.1053/j.gastro.2007.05.051 Rutter, 2004, Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk, Gut, 53, 1813, 10.1136/gut.2003.038505 Ekbom, 1990, Ulcerative colitis and colorectal cancer. A population based study, N Engl J Med, 323, 1228, 10.1056/NEJM199011013231802